Emi Sei

Emi Sei

Auto-generated profile, based on publicly available information

Emi Sei

The University of Texas MD Anderson Cancer Center 1 Department of Systems Biology Houston, Texas

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ASAislyn Schalck
Aislyn Schalck
DSDonastas Sakellariou-Thompson
Donastas Sakellariou-Thompson
MFMarie-Andrée Forget
Marie-Andrée Forget
ESEmi Sei
Emi Sei
THTara G. Hughes
Tara G. Hughes
CBChantale Bernatchez
Chantale Bernatchez
Pancreatic ductal adenocarcinoma (PDAC) has few effective treatments. Immunotherapy, an attractive alternative strategy, remains challenging with the lack of knowledge on the tumor-infiltrating lymphocyte (TIL) landscape in PDAC. To generate a reference of T-cell subpopulations, we profiled 80,000 T cells from 57 PDAC samples, 22 uninvolved/normal samples, and cultured TIL using single-cell transcriptomic and T-cell receptor analysis. These data revealed 20 cell states and heterogeneous distributions of TIL populations. The CD8+ TIL contained a putative transitional GZMK+ population based on T-cell receptor clonotype sharing, and cell-state trajectory analysis showed similarity to a GZMB+PRF1+ cytotoxic and a CXCL13+ dysfunctional population. Statistical analysis suggested that certain TIL states, such as dysfunctional and inhibitory populations, often occurred together. Finally, analysis of cultured TIL revealed that high-frequency clones from effector populations were preferentially expanded. These data provide a framework for understanding the PDAC TIL landscape for future TIL use in immunotherapy for PDAC. Significance: To improve the efficacy of immunotherapy in PDAC, there is a great need to understand the PDAC TIL landscape. This study represents a reference of PDAC TIL subpopulations and their relationships and provides a foundation upon which to base future immunotherapeutic efforts. This article is highlighted in the In This Issue feature, p. 2221

24 February 2025 in Cancer Research
Verified
Journal Article
Closed access
YZYuehui Zhao
Yuehui Zhao
NRNaveen Ramesh
Naveen Ramesh
PXPing Xu
Ping Xu
ESEmi Sei
Emi Sei
MHMin Hu
Min Hu
AZAmado J Zurita
Amado J Zurita
Treatment decisions in metastatic castration-resistant prostate cancer are mostly guided by clinical variables, but efforts to molecularly monitor the disease remain hampered by challenges in acquiring tumor tissue repeatedly. In this study, we simultaneously profiled the genome copy number and exome in longitudinal plasma circulating tumor DNA (ctDNA) acquired before, during, and upon progression to serial treatments with androgen signaling inhibitors and taxane chemotherapy from 60 patients with metastatic castration-resistant prostate cancer (2–10 samples per patient). The genomic data were used to delineate the clonal substructure and evolutionary dynamics of each patient, and an evolutionary dynamic index was developed to measure the longitudinal changes of the tumor subclones. Treatment with androgen signaling inhibitors resulted in greater subclonal selection and population structure changes than taxane treatment. The subclones that emerged in association with serial therapy resistance harbored recurrent aberrations in previously identified and new candidate genes, with particular enrichment in genes related to PI3K–AKT signaling. These findings indicate that the integration of detailed clinical and genomic data can provide a framework for future unbiased genomic applications for ctDNA in the clinic to enable precision medicine. Significance: Profiling of the genomic copy number changes and mutations in circulating tumor DNA collected longitudinally from prostate cancer patients receiving serial life-prolonging therapies elucidates evolutionary dynamics and identifies emerging resistant subclones.

8 June 2026 in Cancer Discovery
Verified
Journal Article
Closed access
HYHanghui Ye
Hanghui Ye
TMThomas O. McDonald
Thomas O. McDonald
REReem Elghaish
Reem Elghaish
ESEmi Sei
Emi Sei
DMDarlan Conterno Minussi
Darlan Conterno Minussi
NNNicholas E. Navin
Nicholas E. Navin
Aneuploidy is a hallmark of human tumors. Although patient-level copy-number alteration (CNA) differences have been investigated extensively in large cohorts, their intratumoral heterogeneity remains understudied. In this study, we conducted a pan-cancer analysis of 94 human tumors at single-cell resolution, representing seven cancer types: bladder, breast, colon, glioblastoma, kidney, lung, and ovarian. Single-cell copy-number profiling was used to analyze 62,646 aneuploid cells, in addition to bulk exome sequencing of most patients and single-nucleus RNA sequencing of six samples. In many cancer types, increased subclonal diversity was associated with higher CNA burden, whole-genome doubling (WGD), TP53 mutations, and increased geographic diversity. Cancer cells from each patient shared a set of truncal CNAs, suggesting evolution from a single ancestral cell. Many tumors accumulated CNAs in bursts of evolution, suggesting that punctuated evolution is common in diverse cancer types. This study greatly improves our knowledge of intratumoral chromosome diversity across human cancers. Significance: This study presents one of the largest pan-cancer single-cell DNA sequencing analyses, profiling intratumoral copy-number heterogeneity across seven major cancer types. The data identified punctuated evolution, clonal origins, subclonal WGD, spatial heterogeneity, and associations between copy-number and transcriptional diversity, with implications for both cancer diagnosis and treatment.

20 May 2025
Verified
Other
Open access
YZYuehui Zhao
Yuehui Zhao
NRNaveen Ramesh
Naveen Ramesh
PXPing Xu
Ping Xu
ESEmi Sei
Emi Sei
MHMin Hu
Min Hu
AZAmado J Zurita
Amado J Zurita
Supplementary Figure S22. Survival analysis of identified genomic alterations that related to chemotherapy resistance or shorter PFS of chemotherapy in cBioPortal

20 May 2025
Verified
Other
Open access
YZYuehui Zhao
Yuehui Zhao
NRNaveen Ramesh
Naveen Ramesh
PXPing Xu
Ping Xu
ESEmi Sei
Emi Sei
MHMin Hu
Min Hu
AZAmado J Zurita
Amado J Zurita
Supplementary Figure S17. Clonal substructure, evolutionary dynamics, and genomic features in relation to clinical parameters

20 May 2025
Verified
Other
Open access
YZYuehui Zhao
Yuehui Zhao
NRNaveen Ramesh
Naveen Ramesh
PXPing Xu
Ping Xu
ESEmi Sei
Emi Sei
MHMin Hu
Min Hu
AZAmado J Zurita
Amado J Zurita
Supplementary Figure S24. Genomic response to Radium-223 therapy